Ultragenyx Pharmaceutical (UP0) Q2 2026 Earnings Report

Positive overall: the call highlighted record quarterly revenue, broad-based product growth (including Evkeeza +50% YoY), expanding patient counts across multiple geographies, improving cash consumption versus Q1, and clear near-term catalysts (two PDUFAs and a pivotal readout). Management articulated a credible path to profitability in 2027 with expense discipline and potential non-dilutive PRV monetization. Offsetting risks include a sizable operating loss and expense run-rate, reliance on binary regulatory outcomes, an unmet primary outcome for setrusumab requiring possible new trials, and readout/regulatory uncertainty for GTX-102, but these are framed as manageable and addressable within management's plan.

Ultragenyx reaffirmed full-year revenue guidance while reporting Q2 2026 results that included $214M total revenue (Crysvita $156M: $94M North America / $54M Latin America & Turkey / $8M Europe; DOJOLVI $27M; Evkeeza $21M, +50% vs Q2 2025; MEPSEVII $10M), total operating expenses of $289M (cost of sales $34M; combined R&D & SG&A $255M, including $34M non‑cash stock‑based comp), net loss of $92M ($0.90/share), $436M in cash & marketable securities as of June 30 and $97M net cash used in operations for the quarter; management reiterated combined R&D & SG&A guidance (2026 flat to down low‑single digits vs 2025) and a targeted ≥15% reduction in 2027 as part of a plan (plus double‑digit revenue growth, contributions from potential DTX‑401 and UX‑111 launches, and monetization of PRVs if approved) to reach profitability in 2027.